CN Patent

CN104513252B — 取代脲衍生物及其在药物中的应用

Assigned to Guangdong HEC Pharmaceutical Co Ltd · Expires 2017-11-10 · 9y expired

What this patent protects

本发明提供了取代脲类衍生物或其立体异构体，几何异构体，互变异构体，氮氧化物，水合物，溶剂化物，代谢产物，酯，药学上可接受的盐或它的前药，及其药物组合物。该类化合物能够用于调节Flt3激酶活性和用于抑制FLT3‑ITD激酶，同时能用于治疗flt3介导或flt3‑ITD引起的疾病的用途。

USPTO Abstract

本发明提供了取代脲类衍生物或其立体异构体，几何异构体，互变异构体，氮氧化物，水合物，溶剂化物，代谢产物，酯，药学上可接受的盐或它的前药，及其药物组合物。该类化合物能够用于调节Flt3激酶活性和用于抑制FLT3‑ITD激酶，同时能用于治疗flt3介导或flt3‑ITD引起的疾病的用途。

Drugs covered by this patent

quizartinib-dihydrochloride (QUIZARTINIB DIHYDROCHLORIDE)

Patent Metadata

Patent number: CN104513252B
Jurisdiction: CN
Classification: —
Expires: 2017-11-10
Drug substance claim: No
Drug product claim: No
Assignee: Guangdong HEC Pharmaceutical Co Ltd
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.